Nordson Divests Design & Development Units to Quasar Medical

Nordson Corporation NDSN recently divested its design and development contract manufacturing business units to Quasar Medical. The financial terms of the transaction have been kept under wraps.Nordson’s shares declined 1.1% yesterday to eventually close the trading session at $222.70.Based in Galway, Ireland and Tecate, Mexico, Nordson Medical's design and development contract manufacturing businesses are engaged in providing a comprehensive solution for complex interventional devices in the medical industry.Inside the HeadlinesWith this buyout, the Galway facility will now operate as Quasar Medical’s innovation center for major processes in manufacturing advanced medical devices, including the development of extrusions, balloons, braiding and complex catheters. The Tecate facility will serve as a manufacturing hub that includes packaging, coating, molding and automated processes.This divestment is in sync with Nordson’s business transformation strategy, which includes disposing of businesses to unlock value for its shareholders. The divestiture will enable NDSN to focus more on its core business and optimize its portfolio within the Medical and Fluid Solutions segment. This will enable Nordson to strengthen its medical component portfolio, which includes several offerings such as cannulas, catheters, medical balloons and fluid management solutions.Zacks Rank & Price PerformanceNordson, with a $12.5 billion market capitalization, currently carries a Zacks Rank #2 (Buy). NDSN is witnessing solid momentum in the Advanced Technology Solutions segment. Strong customer demand for the nonwovens, packaging, consumer non-durable and optical sensors product lines is aiding the company. It aims to expand its market share, product offerings and customer base through strategic acquisitions. Image Source: Zacks Investment ResearchIn the past month, the company’s shares have risen 4.8% compared with the industry’s growth of 2.4%.The Zacks Consensus Estimate for NDSN’s fiscal 2025 (ending October 2025) earnings is pegged at $10.07 per share, up 0.4% from the 60-day-ago figure.Other Stocks to ConsiderSome other top-ranked companies from the same space are discussed below.Flowserve Corporation FLS currently sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.FLS delivered a trailing four-quarter average earnings surprise of 5.5%. In the past 60 days, the Zacks Consensus Estimate for FLS’ 2025 earnings has increased 5.6%.Graham Corporation GHM currently sports a Zacks Rank of 1. GHM delivered a trailing four-quarter average earnings surprise of 64%.In the past 60 days, the consensus estimate for Graham’s fiscal 2025 earnings has increased 15.4%.RBC Bearings Incorporated RBC presently carries a Zacks Rank of 2. It delivered a trailing four-quarter average earnings surprise of 3.8%.In the past 60 days, the Zacks Consensus Estimate for RBC’s fiscal 2026 (ending March 2026) earnings has risen 1.4%.Higher. Faster. Sooner. Buy These Stocks NowA small number of stocks are primed for a breakout, and you have a chance to get in before they take off.At any given time, there are only 220 Zacks Rank #1 Strong Buys. On average, this list more than doubles the S&P 500. We’ve combed through the latest Strong Buys and selected 7 compelling companies likely to jump sooner and climb higher than any other stock you could buy this month.You'll learn everything you need to know about these exciting trades in our brand-new Special Report, 7 Best Stocks for the Next 30 Days.Download the report free now >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report RBC Bearings Incorporated (RBC): Free Stock Analysis Report Flowserve Corporation (FLS): Free Stock Analysis Report Nordson Corporation (NDSN): Free Stock Analysis Report Graham Corporation (GHM): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks Weiter zum vollständigen Artikel bei Zacks